The historic rise of Viagra has long been a benchmark of pharmaceutical success, however its legacy within the broader sector now triggers questions about potential gains. Generic versions are undercutting exclusivity , causing concerns that investing in companies closely tied to Viagra's previous influence could be a problematic strategy, especial